Veru

Q3 FY2026 EarningsQ3 FY26 results beat consensus on earnings, with a GAAP EPS of -$0.30 vs. the -$0.32 expected, and a net loss of $7.0M compared to the anticipated $8.05M. While the company generated zero revenue as expected for this clinical-stage biopharma, research and development expenses spiked to $4.4M due to the full enrollment of the Phase 2b PLATEAU trial. The company maintains a stronger-than-expected cash position of $23.9M, supported by a supply agreement with Novo Nordisk and a recent patent allowance protecting enobosarm through 2044.